Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × SCLC × atezolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 106 Carcinoma, Hepatocellular 61 Breast Neoplasms 44 Neoplasms 41 Small Cell Lung Carcinoma 40 Triple Negative Breast Neoplasms 36 Lung Neoplasms 34 Colorectal Neoplasms 34 Melanoma 31 Urinary Bladder Neoplasms 29 Carcinoma, Transitional Cell 29 Neoplasm Metastasis 28 Carcinoma, Renal Cell 23 Ovarian Neoplasms 19 Stomach Neoplasms 15 Head and Neck Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 14 Uterine Cervical Neoplasms 13 Prostatic Neoplasms 11 Liver Neoplasms 11 Recurrence 10 Solid Tumors 9 Lymphoma 9 Glioblastoma 9 Sarcoma 8 Pancreatic Neoplasms 8 Esophageal Neoplasms 8 Mesothelioma, Malignant 7 Endometrial Neoplasms 7 Carcinoma, Merkel Cell 7

Interventions

Paclitaxel 2 Etoposide 2 Carboplatin 2 sintilimab 1 pembrolizumab 1 olaparib 1 ceralasertib 1 atezolizumab 1 apatinib 1 Topotecan 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06179069 2025-08-15

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Zai Lab (Hong Kong), Ltd.

Phase 1 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡